- Home
- FVRR vs RGNX Comparison
FVRR vs RGNX Comparison
Compare FVRR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FVRR | RGNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.2M | 761.9M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FVRR | RGNX |
|---|---|---|
| Price | $15.96 | $10.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $32.60 | $30.38 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-18-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.40 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $427,401,000.00 | $161,318,000.00 |
| Revenue This Year | $12.79 | $133.58 |
| Revenue Next Year | $5.73 | $45.08 |
| P/E Ratio | $27.91 | ★ N/A |
| Revenue Growth | 12.68 | ★ 91.30 |
| 52 Week Low | $15.61 | $5.04 |
| 52 Week High | $35.40 | $16.19 |
Technical Indicators
Market Signals| Indicator | FVRR | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 35.04 |
| Support Level | $16.50 | $10.45 |
| Resistance Level | $17.32 | $11.78 |
| Average True Range (ATR) | 0.62 | 1.08 |
| MACD | 0.08 | -0.47 |
| Stochastic Oscillator | 17.30 | 19.61 |
Price Performance
Historical ComparisonAbout FVRR Fiverr International Ltd. no par value
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.